<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02686151</url>
  </required_header>
  <id_info>
    <org_study_id>Bhsu</org_study_id>
    <nct_id>NCT02686151</nct_id>
  </id_info>
  <brief_title>The Letrozole Administration During Luteal Phase</brief_title>
  <official_title>The Randomized Clinical Trials of Letrozole Administration During Luteal Phase in Patients Who Have the Risk of Ovarian Hyperstimulation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Affiliated Hospital of Inner Mongolia Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Affiliated Hospital of Inner Mongolia Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of letrozole in patients who have high risk of ovarian
      hyperstimulation syndrome (OHSS) after oocyte retrieval, the incidence of OHSS were
      calculated between letrozole group and supporting treatment group.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Object:

           Infertility patients who frozen all embryos due to the risk of OHSS were randomized
           allocated to letrozole or polygeline injection group. Inclusion criteria meet one of the
           following conditions: (1) oocyte is more than or equal to 20; (2) human chorionic
           gonadotropin (hCG) injection on serum estradiol levels greater than or equal to 5000
           pmol/L; (3) on the day of oocyte unilateral or bilateral ovarian diameter greater than
           or equal to 10 cm (4) follicle puncture is larger than or equal to number 20. After the
           informed consent was signed, letrozole or polygeline injection was randomized allocated
           after oocyte retrieval. OHSS was determined according to Golan diagnosis standards.

        2. Clinical data:

           Including age, infertility duration, body mass index (BMI), basic follicle-stimulating
           hormone (FSH) and luteinizing hormone (LH), antral follicle number (AFC), Gn dosage,
           estradiol level on hCG injection day, the number of oocytes, the number of embryos,
           early onset OHSS incidence, and the existence of ascites.

        3. Reproductive hormone levels:

      1, 4, 7, days after taken letrozole, and the supernatant was collected for serum reproductive
      hormone test.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of early OHSS</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <arm_group>
    <arm_group_label>letrozole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2.5mg/tablet(Jiangsu Hengrui Medicine Co., Ltd. products), orally taken 5mg once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polygeline Injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>500ml and 0.9% Sodium Chloride Injection (250ml) with dexamethasone 1mg intravenous injection，once a day for 2 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>used after oocyte retrieval</description>
    <arm_group_label>letrozole</arm_group_label>
    <other_name>Femara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polygeline</intervention_name>
    <description>used after oocyte retrieval</description>
    <arm_group_label>Polygeline Injection</arm_group_label>
    <other_name>polyegline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Chloride</intervention_name>
    <description>used after oocyte retrieval</description>
    <arm_group_label>Polygeline Injection</arm_group_label>
    <other_name>Natrum muriaticum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>used after oocyte retrieval</description>
    <arm_group_label>Polygeline Injection</arm_group_label>
    <other_name>dexametona</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. oocyte is more than or equal to 20;

          2. hCG injection on serum estradiol levels greater than or equal to 5000 pmol/L; 3. on
             the day of oocyte unilateral or bilateral ovarian diameter greater than or equal to 10
             cm;

        4. follicle puncture is larger than or equal to number 20.

        Exclusion criteria:

        Allergic to the letrozole or polygeline.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yu Wang, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inner Mongolia Medical University affiliated Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Xiujuan Chen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inner Mongolia Medical University affiliated Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Wang, PhD</last_name>
    <phone>+86-18604718958</phone>
    <email>wuai1544@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Affiliated Hospital of Inner Mongolia Medical University</name>
      <address>
        <city>Inner Mongolia</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>He Q, Xu J, Cui S, Li H, Zhang C. [Relationship between letrozole administration during the luteal phase after oocyte retrieval and the early-stage ovarian hyperstimulation syndrome oocurrence]. Zhonghua Fu Chan Ke Za Zhi. 2014 Dec;49(12):909-13. Chinese.</citation>
    <PMID>25608991</PMID>
  </reference>
  <reference>
    <citation>Wang YQ, Yang J, Xu WM, Xie QZ, Yan WJ, Yin TL, Cheng D, Xiao ZN, Li J. [Luteal letrozole administration decreases serum estrogen level but not the risk of ovarian hyperstimulation syndrome]. Beijing Da Xue Xue Bao Yi Xue Ban. 2013 Dec 18;45(6):869-72. Chinese.</citation>
    <PMID>24343064</PMID>
  </reference>
  <reference>
    <citation>Wiwanitkit V. Letrozole and gonadotropins versus luteal estradiol and GnRH-antagonist protocol: additional concerns. Fertil Steril. 2011 Jun 30;95(8):e78; author reply e80. doi: 10.1016/j.fertnstert.2011.05.009. Epub 2011 May 24.</citation>
    <PMID>21605857</PMID>
  </reference>
  <reference>
    <citation>Elassar A, Engmann L, Nulsen J, Benadiva C. Letrozole and gonadotropins versus luteal estradiol and gonadotropin-releasing hormone antagonist protocol in women with a prior low response to ovarian stimulation. Fertil Steril. 2011 Jun;95(7):2330-4. doi: 10.1016/j.fertnstert.2011.03.103. Epub 2011 Apr 22.</citation>
    <PMID>21514582</PMID>
  </reference>
  <reference>
    <citation>Montville CP, Khabbaz M, Aubuchon M, Williams DB, Thomas MA. Luteal support with intravaginal progesterone increases clinical pregnancy rates in women with polycystic ovary syndrome using letrozole for ovulation induction. Fertil Steril. 2010 Jul;94(2):678-83. doi: 10.1016/j.fertnstert.2009.03.088. Epub 2009 Jun 9.</citation>
    <PMID>19515366</PMID>
  </reference>
  <reference>
    <citation>Fatemi HM, Popovic-Todorovic B, Donoso P, Papanikolaou E, Smitz J, Devroey P. Luteal phase oestradiol suppression by letrozole: a pilot study in oocyte donors. Reprod Biomed Online. 2008 Sep;17(3):307-11.</citation>
    <PMID>18764999</PMID>
  </reference>
  <reference>
    <citation>Garcia-Velasco JA, Quea G, Piró M, Mayoral M, Ruiz M, Toribio M, Requena A. Letrozole administration during the luteal phase after ovarian stimulation impacts corpus luteum function: a randomized, placebo-controlled trial. Fertil Steril. 2009 Jul;92(1):222-5. doi: 10.1016/j.fertnstert.2008.04.042. Epub 2008 Aug 16.</citation>
    <PMID>18710719</PMID>
  </reference>
  <reference>
    <citation>Sh Tehrani Nejad E, Abediasl Z, Rashidi BH, Azimi Nekoo E, Shariat M, Amirchaghmaghi E. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphen citrate gonadotropins in controlled ovarian hyperstimulation: a prospective, simply randomized, clinical trial. J Assist Reprod Genet. 2008 May;25(5):187-90. doi: 10.1007/s10815-008-9209-2. Epub 2008 Apr 19.</citation>
    <PMID>18427974</PMID>
  </reference>
  <reference>
    <citation>Ortiz ME, Ortiz RE, Garfield R, Zepeda AJ, Croxatto HB. Progesterone, but not luteal estrogen, is required for the establishment of pregnancy in the new world monkey Cebus apella. Am J Primatol. 2007 Oct;69(10):1131-40.</citation>
    <PMID>17387700</PMID>
  </reference>
  <reference>
    <citation>Barroso G, Menocal G, Felix H, Rojas-Ruiz JC, Arslan M, Oehninger S. Comparison of the efficacy of the aromatase inhibitor letrozole and clomiphene citrate as adjuvants to recombinant follicle-stimulating hormone in controlled ovarian hyperstimulation: a prospective, randomized, blinded clinical trial. Fertil Steril. 2006 Nov;86(5):1428-31. Epub 2006 Sep 14.</citation>
    <PMID>16978619</PMID>
  </reference>
  <reference>
    <citation>Fatemi HM, Kolibianakis E, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online. 2003 Nov;7(5):543-6.</citation>
    <PMID>14680546</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 20, 2015</study_first_submitted>
  <study_first_submitted_qc>February 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2016</study_first_posted>
  <last_update_submitted>February 15, 2016</last_update_submitted>
  <last_update_submitted_qc>February 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Letrozole</keyword>
  <keyword>OHSS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Polygeline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

